Claims
- 1. A method for reducing undesired angiogenesis comprising administering an endothelial progenitor cell which is CD34+, Flk-1+, and tie-2+ and a compound that inhibits angiogenesis, to a location in need of reduced angiogenesis.
- 2. A method for isolating an endothelial progenitor cell which is CD34+, Flk-1+, and tie-2+ comprising:
(a) obtaining human mononuclear cells; (b) selecting cells that express two or more of the following markers: CD34, Flk-1, tie-2′, CD31, UEA-1, selectin, von Willebrand factor, vascular endothelial cadherin, endothelial nitric oxide synthase and or one or more of the following properties: uptake of diacetylated LDL (DiI-acLDL), and lectin binding and (c) isolating the cells.
- 3. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which comprises or is coupled to a cytotoxic agent, and a pharmaceutical carrier, wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 4. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which comprises or is coupled to a co-stimulatory molecule for stimulating an immune reaction, and a pharmaceutical carrier, wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 5. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which comprises or is coupled to an antitumor drug, and a pharmaceutical carrier wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 6. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which comprises or is coupled to an angiogeneisis inhibitor, and a pharmaceutical carrier wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 7. A pharmaceutical composition comprising an endothelial cell (EC) progenitor, an endothelial cell mitogen, and a pharmaceutical carrier wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 8. A method for reducing peripheral vascular trauma during a stent or angioplasty procedure, comprising performing a stent or angioplasty procedure on a patient and administering a modified endothelial progenitor cell which is CD34+, Flk-1+, and tie-2+ to the patient before or after the procedure.
- 9. A method for delivering an agent to a site of angiogenesis in a patient comprising:
administering to the patient an endothelial cell (EC) progenitor cell which comprises or is coupled to the agent, wherein the EC progenitor is CD34+, Flk-1+, and tie-2+.
- 10. A method of screening for the presence of ischemic tissue or vascular injury in a patient comprising contacting the patient with a labelled endothelial cell (EC) progenitor cell which is CD34+, Flk-1+, and tie-2+ and detecting the labelled cells at the site of the ischemic tissue or vascular injury.
- 11. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which is CD34+ and capable of differentiating into a CD34+, Flk-1+, and tie-2+ cell and one or more agents for stimulating differentiation of the CD34+ endothelial cell (EC) progenitor into a CD34+, Flk-1+, and tie-2+ endothelial cell (EC) progenitor cell.
- 12. A pharmaceutical composition comprising an endothelial cell (EC) progenitor which is CD34+ and capable of taking up acetylated LDL Flk-1+ and binding to fibronectin.
- 13. A method for delivering an agent to a site of angiogenesis in a patient comprising:
administering to the patient, an endothelial cell (EC) progenitor cell wherein the EC progenitor is CD34+ and capable of differentiating into a CD34+, Flk-1+, and tie-2+cell, providing one or more agents for stimulating the differentiating.
- 14. A method for improving or preserving left ventricular (LV) function comprising injecting an endothelial cell (EC) progenitor cell which is CD34+ into the left ventricle of a heart.
- 15. A method for improving or preserving cardiac function comprising identifying an area of hibernating cardiac tissue in a heart and contacting the tissue with at least one endothelial cell (EC) progenitor cell which is CD34+.
- 16. A method for inducing or enhancing regeneration of cardiac tissue comprising administering a composition comprising endothelial progenitor cells which are CD34+ to a heart in need of cardiac regeneration.
- 17. A method for enhancing or stimulating blood vessel formation and/or cellular regeneration in a heart comprising delivering an endothelial progenitor cell which is CD34+ to heart tissue in need of blood vessel formation and/or cellular regeneration by introduction of a catheter percutaneously to the endocardial surface of the heart in proximity to the tissue in need.
- 18. A method for expanding a population of endothelial progenitor cells comprising:
a. providing a population of cells which comprises at least one endothelial cell; b. contacting the population with one or more purified endothelial progenitor cells which are CD34+ and capable of differentiating into CD34+, Flk-1+, and tie-2+ cells; c. culturing the population in the presence of a mitogen; thereby expanding cells which are CD34+, Flk-1+, and tie-2+.
Parent Case Info
[0001] This application claims priority to U.S. patent application Ser. No. 09/228,020, filed Jan. 11, 1999 which claims priority to U.S. application Ser. No. 08/744,882, filed Nov. 8, 1996 now U.S. Pat. No. 5,980,887.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09228020 |
Jan 1999 |
US |
Child |
10390559 |
Mar 2003 |
US |